SANA AB Stock

SANION

SE0005794617

Biotechnology & Medical Research

Delayed Nasdaq Stockholm 21:00:00 29/10/2026 +04			5-day change	1st Jan Change
11.45 ^SEK	-0.43%		+6.91%	-45.99%

10-28	Syria says main border crossing with Jordan to resume normal operations Wednesday	RE
10-20	Salesforce Strikes $5.66 Billion Deal to Buy Customer Engagement Platform Braze	MT

Last Transcript: SANA AB

Saniona AB, Q2 2026 Earnings Call, Aug 27, 2026

08-27

More transcripts

Analysts' recommendations: SANA AB

09-07	Affarsvarlden Stops Short of a Buy Call on Saniona	FW
05-28	Redeye raises fair value for Saniona to SEK 20 (19)	FW
11-26	Workday's Q3 Beat Highlights AI and Partner Momentum, RBC Says	MT
11-13	Affärsvärlden Issues Neutral Recommendation for Saniona	FW
25/09/25	Redeye Raises Target Price for Saniona to 19 SEK from 12 SEK	FW

More recommendations

News in other languages: SANA AB

08-24	Discussions Syrie-Israël de désescalade chapeautées par les USA
08-24	Siria e Israel conversan para reducir la tensión: agencia de noticias siria
08-09	Accord entre La Syrie et la Russie sur l'avenir des bases de Tartous et de Hmeimim
07-16	La Syrie déjoue une tentative de contrebande d'armes destinées au Hezbollah
07-07	Explosionen in Damaskus während Macron-Besuch

More news

Managers and Directors: SANA AB

Manager	Title	Age	Since
Janus Schreiber Larsen COO	Chief Operating Officer	54	01/03/2025
Thomas Feldthus CEO	Chief Executive Officer	66	30/04/2022
Palle Christophersen CTO	Chief Tech/Sci/R&D Officer	68	01/01/2014

Director	Title	Age	Since
Jørgen Drejer CHM	Chairman	71	30/04/2022
Carl Johan Bertil Sundberg BRD	Director/Board Member	68	01/01/2015
Anna Ljung BRD	Director/Board Member	46	19/01/2018

More insiders

Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-26 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
29/10/26	SEK 11.45	-0.43%	350,809
28/10/26	SEK 11.50	+6.38%	368,374
27/10/26	SEK 10.81	-3.22%	236,598
26/10/26	SEK 11.17	+1.27%	344,823
23/10/26	SEK 11.03	+2.99%	304,382

Delayed Quote Nasdaq Stockholm

More quotes

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - SANA AB

Company calendar

Market Cap	1.59B 160M 144M 133M 120M 225M 15.24B 227M 632M 7.98B 601M 588M 25.32B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	1.59B 160M 144M 133M 120M 225M 15.24B 227M 632M 7.98B 601M 588M 25.32B	EV / Sales 2026 *	15.4x	EV / Sales 2027 *	7.59x
Free-Float	92.36%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	SANION	Delayed
CBOE	SANIOs	Real-time
Börse Stuttgart	30S	Delayed
Deutsche Boerse AG	30S	Delayed
CBOE	0RQJ	Real-time

10-28	Syria says main border crossing with Jordan to resume normal operations Wednesday	RE
10-20	Salesforce Strikes $5.66 Billion Deal to Buy Customer Engagement Platform Braze	MT
10-20	Saniona submits drug application to FDA	FW
10-20	Saniona AB Submits IND Application For SAN2465 For Major Depressive Disorder	CI
10-15	Jbessa gas export pipeline targeted in northeastern Syria, fire erupts, SANA reports	RE
10-13	Stockholm Stock Exchange ended Tuesday with a slight gain	FW
10-13	Saniona strengthens support for SAN2465 as a fast-acting antidepressant	FW
10-13	Saniona AB Announces New Preclinical Data Reinforcing SAN2465?s Potential As A Rapid-Acting Antidepressant	CI
10-07	20 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
10-07	Saniona Chairman John Haurum Buys Shares for Just Under SEK 0.8m	FW
10-02	28 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
09-29	20 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
09-29	Syria says gas pipeline fire between Al-Shola and Deir Al-Zour caused by "act of sabotage"	RE

10-08	Saniona to attend and present at several conferences in 2026	AQ
10-07	SANA : Notice of extraordinary shareholders' meeting 2026	PU
10-07	Notice of Saniona AB extraordinary shareholders’ meeting	AQ
09-24	Saniona completes toxicology and CMC studies for SAN2465, enabling IND submission by October 2026	AQ
09-07	Saniona (Q2 review): With focus into the clinic	AQ

1 day	-0.17%
1 week	+6.91%
Current month	+17.32%
1 month	+19.46%
3 months	-18.04%
6 months	-18.56%
Current year	-45.99%

SANA AB Stock

Stocks

SANION

SE0005794617

Biotechnology & Medical Research

Valuation: SANA AB

Chart: SANA AB

Latest news: SANA AB

Last Transcript: SANA AB

Analysts' recommendations: SANA AB

Press Releases: SANA AB

News in other languages: SANA AB

Quotes and Performance

Price Extremes

Managers and Directors: SANA AB

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Net sales - Rate of surprise

1 week	10.53	12.08
1 month	8.52	12.08
Current year	8.52	28.3
1 year	8.52	28.3
3 years	1.74	28.3
5 years	1.57	28.3
10 years	1.57	55

Date	Insider	Type	Main position	Quantity	% Market Cap.
07/10/26	John Sørensen Haurum	Buy	Chairman	84,317	0.0611%
09/09/26	John Sørensen Haurum	Buy	Chairman	50,000	0.0362%
01/09/26	Jørgen Drejer	Buy	Founder	9,000	0.0065%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SANA AB	-0.43%	+6.91%	-22.84%	+125.39%	160M
WUXI APPTEC CO., LTD.	+0.34%	-3.03%	+37.45%	+61.06%	64.14B
ARGENX SE	+0.98%	+2.68%	+12.25%	+83.90%	55.53B
LONZA GROUP AG	+1.75%	+2.01%	+13.30%	+105.71%	53.03B
IQVIA HOLDINGS INC.	-1.57%	-0.65%	+26.93%	+56.07%	45.99B
BEONE MEDICINES AG	-0.79%	-2.85%	+17.95%	+99.00%	42.45B
REVOLUTION MEDICINES, INC.	+0.34%	+1.04%	+226.85%	+933.46%	40.45B
CELLTRION, INC.	-0.26%	-4.20%	+10.86%	+45.18%	32.25B
GENMAB A/S	-2.07%	+42.73%	+103.77%	+90.26%	34.47B
WUXI BIOLOGICS (CAYMAN) INC.	-2.72%	-8.79%	+22.58%	-5.63%	24.23B
Average	-0.44%	+3.94%	+44.91%	+159.44%	39.27B
Weighted average by Cap.	-0.21%	+3.13%	+49.49%	+160.87%

	2026 *	2027 *
Net sales	103M 10.4M 9.33M 8.62M 7.81M 14.59M 990M 14.77M 41.07M 518M 39.01M 38.19M 1.64B	209M 21.09M 18.93M 17.5M 15.85M 29.61M 2.01B 29.96M 83.33M 1.05B 79.16M 77.48M 3.34B
Net income	-	-
Net Debt	-	-